Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.41 |
| ▸ | RAB9A | P51151 | 7/20 | 0.41 |
| ▸ | NPC1 | O15118 | 6/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21323168 | 0.86 | SMN1; SMN2 (0.35) | SMN1; SMN2ALDH1A1RAB9ANPC1TP53 | |
| SCHEMBL18552683 | 0.86 | SMN1; SMN2 (0.35) | SMN1; SMN2ALDH1A1RAB9ANPC1TP53 | |
| SCHEMBL18995257 | 0.86 | SMN1; SMN2 (0.35) | SMN1; SMN2ALDH1A1RAB9ANPC1TP53 | |
| SCHEMBL24956330 | 0.86 | SMN1; SMN2 (0.35) | SMN1; SMN2ALDH1A1RAB9ANPC1TP53 | |
| SCHEMBL10197117 | 0.82 | — | — | |
| SCHEMBL19454251 | 0.82 | — | — | |
| SCHEMBL22064870 | 0.82 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1RAB9ANPC1TP53 | |
| SCHEMBL18768237 | 0.82 | LMNA (0.38) | SMN1; SMN2ALDH1A1RAB9ANPC1TP53 | |
| SCHEMBL19298170 | 0.80 | — | — | |
| SCHEMBL11768793 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-07-11 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | BEIGENE SWITZERLAND GMBH (CH) | 2024-06-27 | — | — | US | disclosed |
| WO-2024103400-A1 | POLYCYCLIC COMPOUND AS GPR75 ACTIVATOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 水木未来(北京)科技有限公司 | 2024-05-23 | — | — | WO | disclosed |
| WO-2024092011-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | METABOLEX, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090005399-A1 | Substituted Imidazo[2,1-b]thiazole Compounds and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-01-01 | — | — | US | disclosed |
| US-20080249093-A1 | (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists | MERCK & CO., INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-7420056-B2 | Substituted bicyclic imidazo-3-ylamine compounds | GRUENENTHAL GMBH (DE) | 2008-09-02 | — | — | US | disclosed |
| US-7402606-B2 | Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-22 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20070244119-A1 | 1,3,5-Substituted Phenyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LLC | 2007-10-18 | — | — | US | disclosed |
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | GRUENENTHAL GMBH. (DE) | 2007-07-05 | — | — | US | disclosed |
| US-20070112045-A1 | Triazole ppar modulators | ELI LILLY AND COMPANY | 2007-05-17 | — | — | US | disclosed |
| US-20070003680-A1 | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers | SENOMYX, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005399-A1 | Substituted Imidazo[2,1-b]thiazole Compounds and Uses Thereof | GRM5, GRIK5, GRM1 | SMN1; SMN2 1105/4885ALDH1A1 414/4885RAB9A 1473/4885 |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | SMN1; SMN2 4815/4885ALDH1A1 289/4885RAB9A 4470/4885 |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | SMN1; SMN2 4823/4885ALDH1A1 3026/4885RAB9A 2793/4885 |
| US-20240207267-A1 | (R)-Glutarimide CRBN Ligands and Methods of Use | CRBN, CDR2, CRKL | SMN1; SMN2 2282/4885ALDH1A1 2445/4885RAB9A 3648/4885 |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | SMN1; SMN2 4720/4885ALDH1A1 3041/4885RAB9A 3647/4885 |
| US-20070244119-A1 | 1,3,5-Substituted Phenyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | BACE1, BACE2, PSEN1 | SMN1; SMN2 1431/4885ALDH1A1 989/4885RAB9A 1858/4885 |
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS | SMN1; SMN2 1463/4885ALDH1A1 2777/4885RAB9A 1581/4885 |
| US-20090054475-A1 | treatment of Type II diabetes and other diseases associated with poor glycemic control | SLC5A2, IAPP, GPR119 | SMN1; SMN2 1047/4885ALDH1A1 1333/4885RAB9A 2056/4885 |
| US-20070112045-A1 | Triazole ppar modulators | PPARD, PPARA, PPARG | SMN1; SMN2 4750/4885ALDH1A1 1274/4885RAB9A 4425/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | SMN1; SMN2 3927/4885ALDH1A1 2289/4885RAB9A 2738/4885 |
| US-20080249093-A1 | (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists | S1PR1, S1PR3, S1PR5 | SMN1; SMN2 2376/4885ALDH1A1 740/4885RAB9A 2827/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | SMN1; SMN2 368/4885ALDH1A1 1358/4885RAB9A 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.